Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease

S Tu, S Okamoto, SA Lipton, H Xu - Molecular neurodegeneration, 2014 - Springer
Alzheimer's disease (AD) is a devastating disease characterized by synaptic and neuronal
loss in the elderly. Compelling evidence suggests that soluble amyloid-β peptide (Aβ) …

Journey on naphthoquinone and anthraquinone derivatives: new insights in Alzheimer's disease

M Campora, V Francesconi, S Schenone, B Tasso… - Pharmaceuticals, 2021 - mdpi.com
Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized
by memory loss, cognitive impairment, and functional decline leading to dementia and …

Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment

RL Ashare, M Falcone, C Lerman - Neuropharmacology, 2014 - Elsevier
Nicotine withdrawal is associated with deficits in neurocognitive function including sustained
attention, working memory, and response inhibition. Several convergent lines of evidence …

Asiaticoside mitigates Alzheimer's disease pathology by attenuating inflammation and enhancing synaptic function

S Liu, L Chen, J Li, Y Sun, Y Xu, Z Li, Z Zhu… - International Journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder, hallmarked by the
accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles. Due to the uncertainty of …

Retracted: 'Clinical trials in Alzheimer's disease': immunotherapy approaches

J Delrieu, PJ Ousset, C Caillaud… - Journal of …, 2012 - Wiley Online Library
J. Neurochem.(2012) 120 (Suppl. 1), 186–193. Abstract Recent advances in the
understanding of Alzheimer's disease pathogenesis have led to the development of …

Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia

DJ Foster, DL Choi, PJ Conn… - … disease and treatment, 2014 - Taylor & Francis
Alzheimer's disease (AD) and schizophrenia (SZ) are neurological disorders with
overlap** symptomatology, including both cognitive deficits and behavioral disturbances …

Nootropic medicinal plants: Therapeutic alternatives for Alzheimer's disease

S Vyas, SL Kothari, S Kachhwaha - Journal of Herbal Medicine, 2019 - Elsevier
With the rise in the ageing population in the last few decades, dementia has emerged as a
serious global health issue. Alzheimer's disease (AD) is the most common type of dementia …

Depression and cognitive impairment in older adults

SL Weisenbach, LA Boore, HC Kales - Current psychiatry reports, 2012 - Springer
Late life depression (LLD) is a heterogeneous illness with high rates of treatment resistance.
Cognitive impairment is common in the context of LLD, and LLD may be a prodromal …

Innate immune system and inflammation in Alzheimer's disease: from pathogenesis to treatment

M Serpente, R Bonsi, E Scarpini… - Neuroimmunomodulation, 2014 - karger.com
Immune activation and inflammation, likely triggered by amyloid-beta (Aβ) deposition, play a
remarkable role in the pathogenesis of Alzheimer's disease (AD), which is the most frequent …

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

JD Vardigan, CE Cannon, V Puri, M Dancho… - …, 2015 - Springer
Rationale The standards of care for Alzheimer's disease, acetylcholinesterase inhibitors
such as donepezil (Aricept®), are dose-limited due to adverse side-effects. These adverse …